25 May 2022
By Jonathan Nadler

LYPHE partners with Four 20 Pharma to introduce new 100% natural, unirradiated medical cannabis into the UK

Lyphe Group

In a UK first, LYPHE Group and Four 20 Pharma GmbH have partnered to bring Four 20 Pharma GmbH’s 100% natural unirradiated medical cannabis to the UK.

This is the first time Four 20 Pharma have operated in the UK and the first batch of their ‘420 NATURAL’ product has already arrived in the UK, increasing the options available to patients.

Chris Ashton, Chief Commercial Officer at LYPHE said: “We’re delighted to be working with Four 20 Pharma as their chosen UK partner. We’re confident their high quality unirradiated product along with their 100% natural approach to cultivation will be well received by patients across the UK. We’re always excited to bring new flower to our patients”

Torsten Greif, Chief Sales Officer at Four 20 Pharma GmbH said: “We at Four 20 pharma GmbH are very proud to have successfully entered the British market with our unirradiated products. We have ultimately chosen LYPHE group as a strategic partner, to supply patients with high-quality, 100% natural medical cannabis.  LYPHE Group are one of the pioneers for medical cannabis in the UK”